SOW
CLDX icon

State of Wyoming’s Celldex Therapeutics CLDX Stock Holding History

State of Wyoming’s Portfolio CLDX Stock Details CLDX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2022
Q3 		– Sell
-214
Closed -$6K – 1590
2022
Q2 		$6K Sell
214
-623
-74% -$18.1K ﹤0.01% 1701
2022
Q1 		$29K Sell
837
-271
-24% -$8.66K 0.01% 1325
2021
Q4 		$42K Buy
1,108
+519
+88% +$22.6K 0.02% 1189
2021
Q3 		$32K Sell
589
-448
-43% -$21K 0.02% 868
2021
Q2 		$36K Buy
1,037
+709
+216% +$19.5K 0.02% 823
2021
Q1 		$7K Buy
+328
New +$7.53K 0.01% 417

Other funds holding CLDX

Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
RI
RTW Investments New York $10B AUM 135.35% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
RCM
RA Capital Management Boston, Massachusetts $9.44B AUM 157.3% 1-Year Est. Return
RG
Redmile Group San Francisco, California $1.51B AUM 164.17% 1-Year Est. Return
BG
Bellevue Group Kuesnacht, Switzerland $4.2B AUM 54.85% 1-Year Est. Return
EAM
Eventide Asset Management Boston, Massachusetts $6.05B AUM 76.64% 1-Year Est. Return

State of Wyoming's CLDX Position: Q3 2022 in Review

State of Wyoming sold out of Celldex Therapeutics (CLDX) in Q3 2022, closing a stake of 214 shares — an estimated $6K sold.

State of Wyoming first reported a position in CLDX in Q1 2021 and held it in 6 quarters. The position peaked at $42K in Q4 2021. 159 funds tracked by Wall St. Rank hold CLDX as of Q3 2022.

  • State of Wyoming reported no remaining Celldex Therapeutics position as of Q3 2022 after selling out during the quarter.
  • State of Wyoming sold 214 Celldex Therapeutics shares in Q3 2022, an estimated $6K.
  • State of Wyoming first reported a position in Celldex Therapeutics in Q1 2021 and held it in 6 quarters.
  • State of Wyoming's Celldex Therapeutics position peaked at $42K in Q4 2021.
  • 159 funds tracked by Wall St. Rank held Celldex Therapeutics as of Q3 2022.

Based on State of Wyoming's 13F filing for Q3 2022, filed 14 Nov 2022.